<p>A study by scientists and physicians from Duke University and two Brazilian institutions evaluated the cost-effectiveness of making snake bite antivenom more available in the Amazonas region. Expanding access to antivenom at both hospitals and community health centers would produce the largest benefits, averting up to 3,922 disability-adjusted life-years (DALYs) while yielding economic benefits of up to US$8.98 million.The findings appear in the January 2024 issue of The Lancet Regional Health - Americas.</p>